ERBB2 and breast carcinoma: Hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer, accounting for approximately 70% of all invasive breast cancer cases, is the most prevalent molecular subtype and is also responsible for the majority of breast cancer-related deaths [7, 8].